Smits, Bas M. http://orcid.org/0000-0002-2363-3789
Kleine Budde, Ilona
de Vries, Esther
ten Berge, Ineke J. M.
Bredius, Robbert G. M.
van Deuren, Marcel
van Dissel, Jaap T.
Ellerbroek, Pauline M.
van der Flier, Michiel
van Hagen, P. Martin
Nieuwhof, Chris
Rutgers, Bram
Sanders, Lieke E. A. M.
Simon, Anna
Kuijpers, Taco W.
van Montfrans, Joris M.
Funding for this research was provided by:
Sanquin Plasma Products BV
Article History
Received: 30 April 2020
Accepted: 1 August 2020
First Online: 18 November 2020
Compliance with Ethical Standards
:
: JvM served on an advisory board for Takeda. IKB is working at Sanquin Plasma Products, Market Authorization Holder of Nanogam. EdV received unrestricted research grants from Sanquin, CSLBehring and Shire/Takeda, and served on an advisory board for CSLBehring and a patient awareness panel and professional education program sponsored by Sanquin. MvdF received funding from CSL Behring and Takeda. All other authors declare that they have no conflict of interest.